[1] S. D. Harlow et al., “Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging.,” J. Clin. Endocrinol. Metab., vol. 97, no. 4, pp. 1159–68, Apr. 2012, doi: 10.1210/jc.2011-3362.
[2] J. Drewe, K. A. Bucher, and C. Zahner, “A systematic review of non-hormonal treatments of vasomotor symptoms in climacteric and cancer patients,” pp. 1–29, 2015, doi: 10.1186/s40064-015-0808-y.
[3] P. F. Schnatz, A. Romegialli, J. Abrantes, K. Marakovits, D. Cunningham, and D. M. O’Sullivan, “The North American Menopause Society: From abstract to publication,” Menopause, vol. 15, no. 5, pp. 996–1001, 2008, doi: 10.1097/gme.0b013e318166f026.
[4] Сухих Г.Т., Сметник В.П., Андреева Е.Н., Балан В.Е., Гависова А.А., Григорян О.Р., Ермакова Е.И., Зайдиева Я.З., Ильина Л.М., Касян В.Н., Марченко Л.А., Подзолкова Н.М., Роговская С.И., Сметник А.А., Чернуха Г.Е., Юренева С.В. Менопаузальная гормонотерапия и сохранение здоровья женщин в зрелом возрасте. Клинические рекомендации. 2015, pp. 8–9.
[5] M. G. Munro et al., “The FIGO Ovulatory Disorders Classification System†.,” Hum. Reprod., vol. 37, no. 10, pp. 2446–2464, Sep. 2022, doi: 10.1093/humrep/deac180.
[6] C. K. Welt, Y. Jimenez, P. M. Sluss, P. C. Smith, and J. E. Hall, “Control of estradiol secretion in reproductive ageing.,” Hum. Reprod., vol. 21, no. 8, pp. 2189–93, Aug. 2006, doi: 10.1093/humrep/del136.
[7] N. D. Shaw et al., “Compensatory Increase in Ovarian Aromatase in Older Regularly Cycling Women.,” J. Clin. Endocrinol. Metab., vol. 100, no. 9, pp. 3539–47, Sep. 2015, doi: 10.1210/JC.2015-2191.
[8] E. K. Ofori et al., “Thigh and abdominal adipose tissue depot associations with testosterone levels in postmenopausal females.,” Clin. Endocrinol. (Oxf)., vol. 90, no. 3, pp. 433–439, Mar. 2019, doi: 10.1111/cen.13921.
[9] C. M. Rariy et al., “Higher serum free testosterone concentration in older women is associated with greater bone mineral density, lean body mass, and total fat mass: the cardiovascular health study.,” J. Clin. Endocrinol. Metab., vol. 96, no. 4, pp. 989–96, Apr. 2011, doi: 10.1210/jc.2010-0926.
[10] M. E. Wierman et al., “Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline.,” J. Clin. Endocrinol. Metab., vol. 99, no. 10, pp. 3489–510, Oct. 2014, doi: 10.1210/jc.2014-2260.
[11] S. L. Davison, R. Bell, S. Donath, J. G. Montalto, and S. R. Davis, “Androgen levels in adult females: changes with age, menopause, and oophorectomy.,” J. Clin. Endocrinol. Metab., vol. 90, no. 7, pp. 3847–53, Jul. 2005, doi: 10.1210/jc.2005-0212.
[12] A. R. Cappola et al., “Hormones and Aging: An Endocrine Society Scientific Statement.,” J. Clin. Endocrinol. Metab., vol. 108, no. 8, pp. 1835–1874, Jul. 2023, doi: 10.1210/clinem/dgad225.
[13] S. R. Davis, “Testosterone and the heart: friend or foe?,” Climacteric, vol. 27, no. 1, pp. 53–59, Jan. 2024, doi: 10.1080/13697137.2023.2250252.
[14] C. C. Zouboulis et al., “Skin, hair and beyond: the impact of menopause,” Climacteric, vol. 25, no. 5, pp. 434–442, Sep. 2022, doi: 10.1080/13697137.2022.2050206.
[15] D. A. Schoenaker, C. A. Jackson, J. V Rowlands, and G. D. Mishra, “Socioeconomic position, lifestyle factors and age at natural menopause: a systematic review and meta-analyses of studies across six continents,” Int. J. Epidemiol., vol. 43, no. 5, pp. 1542–1562, Oct. 2014, doi: 10.1093/ije/dyu094.
[16] E. W. Freeman, M. D. Sammel, and R. J. Sanders, “Risk of long-term hot flashes after natural menopause: evidence from the Penn Ovarian Aging Study cohort,” Menopause, vol. 21, no. 9, pp. 924–932, Sep. 2014, doi: 10.1097/GME.0000000000000196.
[17] Улумбекова Г.Э., Худова И.Ю. “Оценка демографического,социального и экономического эффекта при приеме менопаузальной гормональной терапии,” ОРГЗДРАВ: новости, мнения .Вестник ВШОУЗ., vol. 6, no. 4, pp. 23–53, 2020.
[18] C. Costanian, S. Zangiabadi, S. A. Bahous, R. Deonandan, and H. Tamim, “Reviewing the evidence on vasomotor symptoms: the role of traditional and non-traditional factors,” Climacteric, vol. 23, no. 3, pp. 213–223, May 2020, doi: 10.1080/13697137.2019.1711051.
[19] N. Santoro, C. N. Epperson, and S. B. Mathews, “Menopausal Symptoms and Their Management,” Endocrinol. Metab. Clin. North Am., vol. 44, no. 3, pp. 497–515, 2015, doi: 10.1016/j.ecl.2015.05.001.
[20] G. A. Mel’Nichenko et al., “Russian federal clinical guidelines on the diagnostics, treatment, and prevention of osteoporosis,” Probl. Endokrinol. (Mosk)., vol. 63, no. 6, pp. 392–426, 2017, doi: 10.14341/probl2017636392-426.
[21] R. J. Baber, N. Panay, A. Fenton, and IMS Writing Group, “2016 IMS Recommendations on women’s midlife health and menopause hormone therapy.,” Climacteric, vol. 19, no. 2, pp. 109–50, Apr. 2016, doi: 10.3109/13697137.2015.1129166.
[22] F. Palma, A. Volpe, P. Villa, and A. Cagnacci, “Vaginal atrophy of women in postmenopause. Results from a multicentric observational study: The AGATA study,” Maturitas, vol. 83, pp. 40–44, Jan. 2016, doi: 10.1016/j.maturitas.2015.09.001.
[23] S. V. Yureneva, E. I. Ermakova, and A. V. Glazunova, “Genitourinary syndrome of menopause in peri- and postmenopausal patients: Diagnosis and therapy (short clinical guideline),” Akush. Ginekol. (Sofiia)., vol. 5_2016, pp. 138–144, May 2016, doi: 10.18565/aig.2016.5.138-144.
[24] L. N. Wood and J. T. Anger, “Urinary incontinence in women,” BMJ Br. Med. J., vol. 349, p. g4531, Sep. 2014, doi: 10.1136/bmj.g4531.